

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

AdvanCell Pty Ltd.
Petitioner

v.

Sciencons AS and ARTBIO, INC.,
Patent Owner

Post Grant Review No.: PGR2025-00040

PETITIONER'S MOTION TO SEAL

INDEX OF EXHIBITS

Exhibit No.	Description
1001	U.S. Patent No. 12,249,437.
1002	Declaration of Saed Mirzadeh.
1003	Hassfjell, Sindre P. and Hoff, Per, “A Generator for Production of ^{212}Pb and ^{212}Bi ”, Appl. Radiat. Inst., vol. 45, no. 10, pp 1021-25 (1994) (“ Hassfjell-Hoff ”).
1004	WorldCat Index for Hassfjell-Hoff .
1005	International Publication Number WO 01/60417.
1006	File History of U.S. Patent No. 12,249,437.
1007	U.S. Patent No. 5,038,046 (“ Norman ”).
1008	International Atomic Energy Agency, “Radiotracer Generators for Industrial Applications”, IAEA Radiation Technology Series No. 5, IAEA, Vienna (2013) (“ IAEA ”).
1009	Westrøm, Sara; Generalov, Roman; Bønsdorff, Sara B.; and Larsen, Roy H., “Preparation of ^{212}Pb -labeled monoclonal antibody using a novel ^{224}Ra -based generator solution”, Nuclear Medicine and Biology, vol. 51, pp 1-9 (August 2017) (“ Westrøm ”).
1010	WorldCat Index for Westrøm .
1011	Hassfjell, Sindre, “A ^{212}Pb generator based on a ^{228}Th source”, Appl. Radiat. Isot., vol. 55, no. 4, pp 433-439 (2001) (“ Hassfjell-2001 ”).
1012	U.S. Patent Application Publication No. 2006/0286130 (“ Bhagwatwar ”).
1013	U.S. Patent No. 2,130,523.
1014	WorldCat Index for IAEA .
1015	U.S. Patent No. 6,592,843.
1016	Xanjiao Xie, “Dissolution, Formation, and Transformation of the Lead Corrosion Product PbO_2 : Rates and Mechanisms of Reactions that Control Lead Release in Drinking Water Distribution Systems”, All Theses and Dissertations (ETDs), 387 (January 2010), available at https://openscholarship.wustl.edu/etd/387 (“ Xie ”).
1017	U.S. Patent No. 9,281,089.
1018	U.S. Patent No. 6,932,111 (“ Ishigaki ”).
1019	Declaration of Per Hoff.
1020	WorldCat Index for Xie .

Exhibit No.	Description
1021	Excerpts of The American Heritage Dictionary of the English Language, 5 th ed. (2016).
1022	Declaration of Jennifer Librach Nall.
1023	Conroy Deposition Transcript.
1024	Conroy Exhibit 6, Excerpt of homedepot.com.
1025	Conroy Deposition Exhibit 8, Excerpt of VAT website showing VAT Gate Valve
1026	ARTBIO, “ARTBIO and Nucleus RadioPharma Announce Collaboration to Manufacture GMP-Grade Therapeutic Products Containing Radioisotope Pb-212 to Support Emerging Clinical Trials” (May 7, 2024), https://artbio.com/artbio-nucleus-radiopharma-collaboration-manufacture-gmp-grade-therapeutic-products-radioisotope-pb-212-support-emerging-clinical-trials .
1027	Conroy Exhibit 3: Fraiser Kansteiner, “Nucleus RadioPharma Links Up With ARTBIO to Help Produce Prostate Cancer Candidate for Clinical Trials,” Fierce Pharma (May 7, 2024), https://www.fiercepharma.com/pharma/nuclear-medicine-cdmo-nucleus-links-artbio-help-produce-prostate-cancer-radiotherapy .
1028	Conroy Exhibit 4: ARTBIO, “ARTBIO and Nucleus RadioPharma Announce Collaboration to Manufacture GMP-Grade Therapeutic Products Containing Radioisotope Pb-212 to Support Emerging Clinical Trials” (May 7, 2024), https://artbio.com/artbio-nucleus-radiopharma-collaboration-manufacture-gmp-grade-therapeutic-products-radioisotope-pb-212-support-emerging-clinical-trials .
1029	National Library of Medicine, “Study of Alpha Radioligand Therapy AB001 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) (ARTISAN)” (last updated Apr. 7, 2026), https://clinicaltrials.gov/study/NCT07214961
1030	ARTBIO, “ARTBIO Announces Dosing of Two Cohorts with AB001 in ARTISAN, a Phase 1 Alpha Radioligand Therapy Clinical Trial for Metastatic Castration Resistant Prostate Cancer” (Jan. 12, 2026), https://artbio.com/ARTBIO-Announces-dosing-of-Two-Cohorts-with-AB001

In accordance with 37 C.F.R. § 42.14, Petitioner moves to seal EX1023 (the deposition transcript of Charles Conroy, dated April 2, 2026), filed herewith, in accordance with the pending Joint Motion for Entry of the Default Protective Order. See Paper 18.

Certain portions of this deposition transcript were designated confidential by Patent Owner and its expert Mr. Conroy during the deposition of Mr. Conroy. This document should not be public because they contain confidential information about Mr. Conroy's financial interest in a third party. Members of the public may refer to the redacted copy of Exhibit 1023. This information should not be public because it relates to confidential information about Patent Owner's expert, Mr. Conroy.

Date: April 29, 2026

Respectfully submitted,

/s/ Jennifer Librach Nall

Jennifer Librach Nall

Reg. No. 57,053

DLA Piper LLP US

303 Colorado Street, Suite 3000

Austin, TX 78701

Phone: + 1 512 457 7249

Fax: + 1 512 721 2249

jennifer.nall.ptab@us.dlapiper.com

Attorney for Petitioner, AdvanCell
Isotopes Pty Ltd

CERTIFICATE OF SERVICE

The undersigned certifies that on April 29, 2026, a true and correct copy of the forgoing document was served by emailing a copy of same (by agreement) to the following attorneys for the Patent Owner:

Michael T. Rosato (mrosato@wsgr.com)

Patrick M. Medley (pmedley@wsgr.com)

Michael J. Hostetler (mhostetler@wsgr.com)

Respectfully submitted,

/s/ Jennifer Librach Nall
Jennifer Librach Nall